Search
Ditazole
go.drugbank.com/drugs/DB08994ApprovedWithdrawnDitazole's analgesic and antipyretic effects are similar to phenylbutazone. Additionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.
MCMV5322A
go.drugbank.com/drugs/DB17763InvestigationalMCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]
MCMV3068A
go.drugbank.com/drugs/DB17764InvestigationalMCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]
SR-9009
go.drugbank.com/drugs/DB14013ExperimentalSR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
TAK-611
go.drugbank.com/drugs/DB17644InvestigationalFirst developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.
Deanol
go.drugbank.com/drugs/DB13352InvestigationalDeanol is commonly referred to as 2-(dimethylamino)ethanol, dimethylaminoethanol (DMAE) or dimethylethanolamine (DMEA). It holds tertiary amine and primary alcohol groups as functional groups.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsGTP-506
go.drugbank.com/drugs/DB17682ExperimentalGTP-506 is a gene therapy formed by two vectors, a nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene to provide
AVR-RD-02
go.drugbank.com/drugs/DB17650InvestigationalIt consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified _ex vivo_ with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that, … after reverse transcription, results in codon-optimized, complementary deoxyribonucleic acid (cDNA) that, upon its integration into human genome, encodes for functional human glucocerebrosidase (GCase
Rabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.